More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.

Our health care system needs to do a better job of diagnosing and supporting people with cannabis-related diseases,” a ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...

A federal judge has tossed out a lawsuit from Humana that attempted to reinstate higher quality ratings to its 2025 Medicare ...

The people most at risk from suicide aren’t adolescents in angst or those experiencing a midlife lull, but men age 75 and ...

In a surprise, a FDA advisory panel voted that risks tied to a GSK blood cancer drug called Blenrep outweighed the benefits ...

A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

Robert F. Kennedy Jr. just named Mark Cruz, a Klamath member, his top tribal health adviser. In a Q&A, Cruz emphasized tribal ...

WASHINGTON — Congressional Republicans early on Friday morning passed legislation to take back money they had already ...

Unlock faster trials & better ROI in health data with STAT. Join experts on Aug 14 to build a smarter technology ...